Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Status:
Completed
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well umbilical cord blood transplant from a donor works
in treating patients with hematological cancer. Giving chemotherapy and total-body
irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of
cancer and abnormal cells and helps stop the patient's immune system from rejecting the
donor's stem cells. When the healthy stem cells from an unrelated donor, that do not exactly
match the patient's blood, are infused into the patient they may help the patient's bone
marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
transplanted cells from a donor can make an immune response against the body's normal cells
(called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and
after transplant may stop this from happening.